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8SCritical appraisal of surgical revascularization for
critical limb ischemia
Michael S. Conte, MD, San Francisco, Calif
Peripheral artery disease is growing in global prevalence and is estimated to afﬂict between 8 and 12 million Americans.
Its most severe form, critical limb ischemia (CLI), is associated with high rates of limb loss, morbidity, and mortality.
Revascularization is the cornerstone of limb preservation in CLI, and has traditionally been accomplished with open
surgical bypass. Advances in catheter-based technologies, coupled with their broad dissemination among specialists, have
led to major shifts in practice patterns in CLI. There is scant high-quality evidence to guide surgical decision making in
this arena, and market forces have exerted profound inﬂuences. Despite this, available data suggest that the expected
outcomes for both endovascular and open surgery in CLI are strongly dependent on deﬁnable patient factors such as
anatomic distribution of disease, vein quality, and comorbidities. Optimal patient selection is paramount for maximizing
beneﬁt with each technique. This review summarizes some of the existing data and suggests a selective approach to
revascularization in CLI, which continues to rely on vein bypass surgery as a primary option in appropriately selected
patients. (J Vasc Surg 2013;57:8S-13S.)Peripheral artery disease (PAD) is a growing public
health issue in the United States and around the globe.
Currently estimated to afﬂict more than 8 million Ameri-
cans, PAD and its related health care expenditures have
increased dramatically with recent demographic and risk
factor trends, particularly the rise in diabetes.1 Its most
advanced form, critical limb ischemia (CLI), is associated
with high rates of limb loss, morbidity, and mortality.2
Recent estimates of the Medicare expenditures associated
with treatment for CLI exceed 3 billion dollars annually.
These costs are driven largely by in-hospital care related
to procedures, primarily revascularizations, among which
are the growing volume of endovascular interventions.3-5
Despite the magnitude of the problem, there is scant
high-quality evidence to guide medical and surgical deci-
sion making in CLI.
CLI is deﬁned clinically as a syndrome of advanced
ischemia manifest by either rest pain in the foot or tissue
loss (Rutherford classiﬁcation 4-6, Fontaine III/IV).
However, this deﬁnition encompasses a broad range of
disease severity and natural history, which greatly compli-
cates comparisons of results in the literature. Indeed, the
lack of a more precise disease staging system has been
a major impediment in the ﬁeld. The diagnosis of CLI is
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://dx.doi.org/10.1016/j.jvs.2012.05.114severely compromised foot perfusion, although there is
a lack of consensus on threshold values. Commonly
accepted values of ankle pressure (<50 mm Hg for rest
pain, <70 mm Hg for tissue loss) or toe pressure
(<30 mm Hg for rest pain; <50 mm Hg for tissue loss)
deﬁne critical levels of ischemia. A dire natural history is
generally ascribed to the diagnosis of CLI, with 15%-20%
mortality and up to 40% limb loss within a year of diag-
nosis.2 CLI also has a profound negative impact on patient
quality of life, with wound care and analgesic requirements,
impaired ambulation, reduced level of function, and recur-
rent hospitalizations. The primary therapeutic goals in CLI
are relief of pain, healing of wounds, preservation of a func-
tional limb, and maintenance of ambulatory status. These
goals are directly related to timely and effective revascular-
ization of the lower extremity. For some patients, primary
amputation is the most appropriate therapy. Most patients
have signiﬁcant comorbidities including other manifesta-
tions of atherosclerosis. Minimizing the risk of mortality
and major cardiovascular events is central to the care of
the patient with CLI and is addressed by the appropriate
use of diagnostics, medical therapies, and risk factor
modiﬁcation.6
REVASCULARIZATION STRATEGIES IN CLI:
KEY FACTORS IN THE INITIAL EVALUATION
Clinical decision making in the patient with CLI must
carefully weigh a variety of patient, anatomic, and proce-
dural variables (Fig). The complexity of these decisions
emphasizes the importance of broad training in vascular
disease and longitudinal patient care experience. The
general health and life expectancy of the patient, as well as
their ambulatory status, are a physician’s foremost consider-
ations. Some patients with advanced comorbidities may not
be suitable for open bypass surgery or a general anesthetic.
Conservative therapy or less invasive modalities may be
most appropriate in the frail or dependent patient.However,
the available data suggest that the 30-day mortality rates for
Fig. Key factors involved in selecting the revascularization strategy in critical limb ischemia (CLI). Surgical risk refers to
expected 30-day mortality. TASC, TransAtlantic Inter-Society Consensus; GSV, great saphenous vein; ENDO,
endovascular therapy.
Table I. Periprocedural (30-day) mortality and major
morbidity after treatment of critical limb ischemia (CLI)
Open
bypass
Endovascular
therapy Amputation
Mortality 2.1%-5.4%11-16
(2.7%)a
2%-8%4,6-9
(2.7%)a
6%-13%13,17,18
MACE 6.2%a N/A N/A
Amputationb 1.9%a 3.1%a
1.7%-11.6c
N/A
MALE 6.1%a 16.2%a N/A
MACE, Major adverse cardiovascular event inclusive of death, myocardial
infarction, and stroke; MALE, major adverse limb event inclusive of major
amputation, thrombectomy/thrombolysis, open bypass graft, and major
open revision.
aValue from the Society for Vascular Surgery Critical Limb Ischemia Objective
Performance Goals data set22 (www.criticallimb.org).
bTranstibial or above.
cEstimated rates from reference4 range depending on Rutherford presentation
(4-6).
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(2%-6%)11-16 in CLI are similar, whereas the rate is generally
higher for primary amputation (6%-12%)17-19 than for either
form of revascularization (Table I). Obviously, these data
reﬂect primarily the medical acuity of the patients selected
for each approach, and highlight the challenges inherent in
the management of CLI.
A thorough examination of the limb and foot deﬁnes
the severity of ischemia, the likelihood of functional
salvage, and the presence of critical factors such as local
sepsis, soft tissue compromise, venous disease, and prior
surgical incisions. A careful history of prior vascular inter-
ventions in the limb is paramount to developing a strategy,
and detailed reports should be obtained. The anatomic
distribution of disease is determined by imaging studies
such as computed tomography angiography, magnetic
resonance angiography, duplex ultrasound scanning, and
catheter-based angiography. Finally, the availability and
quality of autogenous vein for bypass must be ascertained,
and this is best done by ultrasound vein mapping. Only
when all of this information is available can the optimal
revascularization strategy be deﬁned for the individual
patient with CLI.
The anatomic distribution of arterial occlusive disease is
a dominant factor in developing the strategy, because of
its known relationship to the success of treatment modali-
ties. This review focuses on infrainguinal occlusive disease,
where the typical anatomy encountered in the patient with
CLI is challenging for endovascular therapy. Common
femoral disease, long-segment femoropopliteal occlusions,
multilevel disease, and diffuse infrapopliteal disease arecommon patterns in CLI.20 The current TransAtlantic
Inter-Society Consensus (TASC) II guidelines provide
a framework for decision making based primarily on disease
anatomy, with surgery preferred for more severe lesions
(TASC C/D), although there is considerable controversy
around these guidelines and variability in their application.
The TASC classiﬁcation scheme does not take into account
all of the aforementioned clinical and patient-level factors
and has had the unintended consequence of encouraging
a lesion-centric mentality in the care of the patient
with PAD. Another important caveat about the TASC
Table II. Key midterm outcomes of endovascular
therapy for critical limb ischemia (CLI) from selected
series
Author
No. of
patients Outcome Rate
Follow-up,
years
Laird et al32 155 AFS 82% 0.5
Giles et al8 176 RAS/LS 39%/84% 1
DeRubertis et al33 184 LS 88% 1
Conrad et al9 447 LS 88% 1
Romiti et al7 2653
(meta-analysis)
LS 82% 3
AFS, Amputation-free survival; LS, limb salvage; RAS, reintervention,
amputation, or stenosis >60%.
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the efﬁcacy of endovascular treatments, the primary deter-
minant of successful open bypass surgery is conduit (vein)
quality. Therefore, a careful assessment of both of these
key anatomic variables is important to deﬁne an optimal
strategy for revascularization.
PRINCIPLES OF REVASCULARIZATION IN CLI
Regardless of the mode of revascularization selected,
certain fundamental principles are critical to a successful
outcome in CLI. High-quality vascular imaging is manda-
tory, generally obtained by digital subtraction angiography,
with multiple dedicated views of the ankle and foot. A goal
of restoring straight-line ﬂow to the foot is especially
important in the setting of tissue loss. Pulsatile blood
ﬂow optimizes the local environment for wound healing.
Treating proximal lesions in the presence of a distal occlu-
sion will predictably be inadequate for patients with tissue
loss or infection. After intervention, surveillance and vigilant
follow-up are required to assess, and to maintain, hemody-
namic improvement. Sustained hemodynamic improvement
in the treated limb is the most direct measure of effective revas-
cularization therapy. At scheduled follow-up visits, clinical
examination, ankle/toe pressures, and duplex ultrasound
scanning of the arteries or bypass graft are performed to
identify recurrent narrowings or occlusions. Many, if not
most, patients with CLI undergo repeat interventions over
time because of the frequency of restenosis and graft disease.
A low threshold for reintervention, including early conver-
sion to open bypass surgery for endovascular treatment
failure, is employed to avoid further tissue loss and maintain
functional limb salvage.
ENDOVASCULAR THERAPY FOR CLI
Enthusiasm for endovascular treatment in CLI has
been fueled by the continued evolution of catheter-based
technologies, the broad dissemination of the requisite skills
among vascular specialists, and the signiﬁcant potential
advantages of a less invasive approach in a sick population.
These include presumed lower mortality and complication
rates, although recent data suggest this assumption may be
ﬂawed.4,9 Recovery from a percutaneous procedure is faster
than from open surgery and avoids wound morbidity and
other surgical complications. Moreover, it is often argued
that the treatments can be repeated as needed without
“burning bridges” for the patient. Unfortunately, these
potential advantages are not always realized in practice,
and a review of the contemporary literature provides
a more sanguine view of the outcomes obtained after endo-
vascular interventions in CLI.
Like any therapy, there are also signiﬁcant limitations
and disadvantages to be considered for endovascular
treatment of CLI. These include reduced efﬁcacy of the
revascularization, in terms of both acute hemodynamic
improvement and sustained hemodynamic success. Clearly,
there is a risk of limb deterioration related to failures and
complications of the percutaneous intervention, and
surgical options may be affected, for example, by the useof stents at preferred inﬂow or outﬂow anastomosis sites
or by the loss of distal outﬂow to the foot.21,22 There is
a cost to both the patient and the health care system of
ineffective or nondurable treatments.4,5 Recurrent symp-
toms, delayed healing, further tissue loss, and repeat inter-
ventions are more likely when the initial revascularization is
ineffective or improved perfusion is not sustained.
Recent data suggest that the early and midterm
outcomes of endovascular treatment in CLI may be accept-
able in well-selected patients and experienced centers
(Table II). Limb salvage rates greater than 80% are re-
ported at 1-3 years. All series demonstrate that restenosis
and reintervention are extremely common. Unfortunately,
comparison of outcomes between series is fraught with
difﬁculty because techniques are not standardized, cohorts
are heterogeneous, numbers are modest, and observations
often limited by variable follow-up time and quality. Most
series are heavily skewed to less severe presentations (Ruth-
erford 4/5). A full review of this topic is well beyond the
scope of the present article. However, consistent themes
emerge with respect to the factors associated with poor
outcome for endovascular treatment in CLI. Disease
severity (TASC D anatomy), tissue loss, and diabetes
consistently predict poorer outcomes after endovascular
treatment. There remain many unknowns, particularly
with respect to the outcomes of interventions for popliteal
and infrapopliteal disease. Knowledge of the risks and limi-
tations of endovascular treatment is important in decision
making, which is ﬁnalized at the time of diagnostic
angiography and prior to attempting guidewire traversal
of lesions. Although technical success in the reported series
is generally high, fueling the enthusiasm of practitioners,
the data clearly indicate that technical success does not
equate to clinical success for the patient. Most research
emphasis in device technology has been driven toward
the technical element, although the recent development
of drug-coated balloons and stents offers hope for
improving the durability of these interventions. The full
potential beneﬁt for endovascular interventions in CLI
will not be realized until restenosis is dramatically reduced
for the challenging disease patterns commonly encoun-
tered in these patients.
Table III. Contemporary 1-year results of autogenous
vein surgical bypass for critical limb ischemia (CLI) from
multicenter prospective trials
PREVENT III
(n ¼ 1404)
BASIL
(n ¼ 186)
SVS OPG23
(n ¼ 838)
Survival 84% 81% 86%
Limb salvage 88% 88% 89%
Amputation-free survival 78% 72% 77%
Freedom from major
adverse limb event
75% 80% 77%
BASIL, Bypass Versus Angioplasty in Severe Ischaemia of the Leg; OPG,
Objective Performance Goals; PREVENT III, Project of Ex Vivo Graft
Engineering via Transfection III; SVG, Society for Vascular Surgery.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2S Conte 11SSURGICAL BYPASS FOR CLI: CONTEMPORARY
OUTCOMES
Results of autogenous vein bypass grafting for CLI are
well documented in many single-center reports, meta-
analyses, and multicenter trials. Autogenous vein grafts to
tibial or pedal targets for CLI function for 5 years or longer
in 50%-70% of patients. Limb salvage rates generally exceed
80% at 5 years.2 The procedure is versatile with respect to
anatomic circumstances and patient risk factors. Periopera-
tive mortality is acceptably low (3%) and not dissimilar to
percutaneous intervention. However, there are important
limitations and risks to be considered, including postoper-
ative morbidity, which is signiﬁcant (20%). Wound compli-
cations are frequent (10%-20%) and may incur prolonged
hospitalization, additional procedures, outpatient care,
and patient discomfort. Systemic complications such as
cardiac, pulmonary, and renal problems are not rare, and
recovery in such cases may be prolonged. Availability of
good-quality venous conduit is an important limitation in
at least 20% of surgical candidates, and other alternatives
such as prosthetic grafts are inferior. De novo stenosis
within the vein graft conduit occurs in 30%-40% of patients
within the ﬁrst 2 years of bypass, mandating a program of
surveillance and reintervention to preserve long-term
patency. Most importantly, distal bypass surgery for limb
salvage is one of the most technically demanding proce-
dures in vascular surgery, and there is signiﬁcant variability
in training, experience, and skill level among practitioners.
It is likely that this plays a signiﬁcant role in local practice
patterns as well as in the outcomes realized.
The Project of Ex Vivo graft Engineering via Transfec-
tion III (PREVENT III) and Bypass Versus Angioplasty in
Severe Ischaemia of the Leg (BASIL) trials provide a broad
snapshot of limb salvage surgery in both North America
and the United Kingdom (Table III). The BASIL bypass
cohort included 25% prosthetic grafts that performed
poorly, whereas the PREVENT III cohort was composed
exclusively of vein bypass grafts. The reader is referred to
the key reports from these individual trials,10,12 the data
from which have recently been combined in an effort by
the Society for Vascular Surgery to develop performance
goals in CLI.23 A perioperative (30-day) mortality rate of3%, major adverse cardiovascular event (MACE) rate of
6%, graft occlusion rate of 5%, and amputation rate of 2%
are the expected early results for open bypass surgery
with vein. At 1 year, expected limb salvage is 88% and
amputation-free survival is 77% for the broad CLI cohort
represented by these surgical trials. A major adverse limb
event outcome was deﬁned as a key patient-centered end
point consisting of major amputation, need for thrombol-
ysis/thrombectomy, placement of a new open bypass, or
major graft revision (other than simple patch). Freedom
from major adverse limb events at 1 year was 77% in the
Society for Vascular Surgery Objective Performance Goals
surgery cohort.
It is important to note that all of the key CLI outcomes
reported in the Society for Vascular Surgery Objective
Performance Goals trial were strongly dependent on base-
line patient factors, and heterogeneity across these variables
would be expected to have a signiﬁcant inﬂuence on the ex-
pected outcomes. The most important factors included age
(>80), tissue loss, infrapopliteal disease, and a poor-quality
venous conduit. Because these factors exert signiﬁcant
effects, nonrandomized comparisons between different
cohorts without risk stratiﬁcation are likely to lead to erro-
neous conclusions.
Technical factors are critical to the short- and long-
term success of bypass surgery, with vein quality being
paramount.24,25 A single-segment great saphenous vein
graft with a diameter $3.5 mm is the optimal conduit
for leg bypass. Nearly half of the patients in the PREVENT
III trial had their bypasses completed with such conduits,
experiencing a 1.7% 30-day failure rate, 87% secondary
patency, and 91% limb salvage at 1 year. Moreover, the
level of distal anastomosis (a surrogate for arterial disease
pattern) is not an important limitation for a good-quality
vein; that is, tibial/pedal bypasses with $3.5 mm single-
segment great saphenous vein grafts perform equally
as well as popliteal bypass grafts in terms of all measured
outcomes including patency. Further, diabetes does not
have a negative impact on infrainguinal vein graft perfor-
mance, a fact that has been reported in multiple large insti-
tutional series as well as in the multicenter PREVENT III
cohort.26,27 Overall, these contemporary data conﬁrm that
a saphenous vein bypass graft remains the gold standard for
durable revascularization in the patient with CLI.
Many authors have attempted to deﬁne preoperative
factors that predict outcomes for infrainguinal bypass
surgery. Using the PREVENT III cohort, a risk score was
recently developed and validated to predict amputation-
free survival after surgical bypass for CLI.28 Five baseline
variables—dialysis dependency, tissue loss, age>75, anemia
(hematocrit<30%), and history of advanced coronary artery
disease—can be used to stratify patients for expected
outcome. A high-risk cohort was deﬁned based on a
weighted scoring system and was represented by 9% of
the PREVENT III population and 6% of a multicenter
surgical consortium database.29 For this high-risk group,
amputation-free survival at 1 year was approximately 50%,
suggesting that one in two such patients did not experience
JOURNAL OF VASCULAR SURGERY
12S Conte February Supplement 2013ameaningful beneﬁt from the operation. Clearly, careful risk
stratiﬁcation is paramount to selecting candidates for both
endovascular and surgical bypass in CLI.
At present, only one randomized trial—BASIL—has
directly compared the outcomes of endovascular and
open bypass strategies for advanced limb ischemia. The
design of BASIL and its potential limitations have been
described in detail elsewhere. However, it constitutes the
only level I evidence currently available in the ﬁeld.30,31
The investigators randomized 452 patients with “severe
limb ischemia” to surgery-ﬁrst or balloon angioplasty-ﬁrst
treatment strategies and had long-term follow-ups to 5
years or longer in most patients. Most of the patients
randomized in BASIL had moderate to severe disease
either above or below the knee, and commonly only a single
segment was treated. Isolated tibial angioplasty was rarely
performed, and 25% of the bypass grafts were prosthetic.
All of these factors would tend to weigh in favor of better
outcomes for angioplasty. At 1 year, there was no differ-
ence in amputation-free or overall survival. However, for
patients who survived to 2 years (70% of the cohort), there
was a survival advantage associated with the bypass-ﬁrst
assignment and a trend toward improved amputation-free
survival. Moreover, crossover to bypass surgery was signif-
icant in the trial, and the analysis by treatment received
suggested that patients who had bypass after a failed initial
angioplasty fared much more poorly than patients who had
an initial bypass.21 This observation directly refutes the
“free-shot” notion of angioplasty in CLI and has been
conﬁrmed in other recent multicenter cohorts.22 The
BASIL authors concluded that bypass surgery with vein
offers the best long-term outcome and is the preferred
treatment for patients expected to survive to 2 years or
longer (approximately 70% of their cohort). They also
opined that prosthetic bypass was associated with poor
results, and therefore, angioplasty may be preferred where
possible in patients lacking adequate venous conduit.
CONCLUSIONS
Any thoughtful review of the available data leads one to
the conclusion that neither an “endo-ﬁrst” nor a “bypass-
ﬁrst” dogma is an appropriate posture in patients with
CLI. Instead current evidence, combined with individual
experience, should be used to select the optimal approach
in each case. Anatomic factors exert a strong inﬂuence on
surgical decision making; however, the physiological state
of both the limb and the overall patient will dominate
the outcome. In this highly vulnerable population, much
is at stake, and adverse events are common. Early failures,
generally a result of either a ﬂawed revascularization
strategy or a technical failure, often lead to rapid deteriora-
tion of the limb. Furthermore, most patients with true CLI
will experience a recrudescence of symptoms if the inter-
vention fails at a later time. Sustained hemodynamic success
is therefore the primary objective of revascularization.
Open surgical bypass continues to be a primary treatment
choice in a signiﬁcant proportion of patients and is not
infrequently required after failed endovascular intervention.Aggressive medical management, technical proﬁciency, and
postprocedural surveillance are cornerstones of success.
Wound management and foot care are likewise critical
both to achieve and to maintain long-term function. All
patients with CLI should be cared for by dedicated special-
ists with training and experience in these realms, ideally in
a coordinated multidisciplinary center. As technology
continues to improve, better-quality evidence in the form
of carefully conducted clinical trials and registries is sorely
needed to improve patient outcomes and control costs.REFERENCES
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